Search Results - "WIEDER, Hinrich A"

Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment by WIEDER, Hinrich A, BRUCHER, Björn L. D. M, WEBER, Wolfgang A, ZIMMERMANN, Frank, BECKER, Karen, LORDICK, Florian, BEER, Ambros, SCHWAIGER, Markus, FINK, Ulrich, SIEWERT, Jörg Rüdiger, STEIN, Hubert J

“…To evaluate the time course of therapy-induced changes in tumor glucose use during chemoradiotherapy of esophageal squamous cell carcinoma (ESCC) and to…”
Get full text

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma by HERRMANN, Ken, WIEDER, Hinrich A, PESCHEL, Christian, SCHWAIGER, Markus, DECHOW, Tobias, BUCK, Andreas K, SCHÖFFEL, Marion, KRAUSE, Bernd-Joachim, FEND, Falko, SCHUSTER, Tibor, ZUM BÜSCHENFELDE, Christian Meyer, WESTER, Hans-Jürgen, DUYSTER, Justus

“…Purpose: To evaluate 3′-deoxy-3′-[ 18 F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin's…”
Get full text

Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy by Beer, Ambros J, Wieder, Hinrich A, Lordick, Florian, Ott, Katja, Fischer, Michael, Becker, Karen, Stollfuss, Jens, Rummeny, Ernst J

“…To prospectively evaluate multi-detector row computed tomography (CT) in the assessment of early response during neoadjuvant chemotherapy for adenocarcinoma of…”
Get more information

Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters by Wieder, Hinrich A

“…Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer.Different radionuclides…”
Get full text

PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer by Wieder, Hinrich A, Geinitz, Hans, Rosenberg, Robert, Lordick, Florian, Becker, Karen, Stahl, Alexander, Rummeny, Ernst, Siewert, Jörg R, Schwaiger, Markus, Stollfuss, Jens

“…Positron emission tomography (PET) using 18F-labelled 3'-deoxy-3'-fluorothymidine (FLT) was assessed for therapy monitoring in patients with rectal cancer…”
Get full text

Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer by Ott, Katja, Herrmann, Ken, Schuster, Tibor, Langer, Rupert, Becker, Karen, Wieder, Hinrich A., Wester, Hans-Jürgen, Siewert, Jörg-Rüdiger, Büschenfelde, Christian Meyer zum, Buck, Andreas K., Wilhelm, Dirk, Ebert, Matthias P. A., Peschel, Christian, Schwaiger, Markus, Lordick, Florian, Krause, Bernd Joachim

“…Background Metabolic imaging of gastric cancer is limited due to the 30% of primary tumors that are not 18 F-fluorodeoxyglucose (FDG) avid. In contrast, the…”
Get full text

Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction by Wieder, Hinrich A, Ott, Katja, Lordick, Florian, Becker, Karen, Stahl, Alexander, Herrmann, Ken, Fink, Ulrich, Siewert, Jörg Rüdiger, Schwaiger, Markus, Weber, Wolfgang A

“…Positron-emission-tomography with the glucose analog fluorodeoxyglucose (FDG-PET) has shown encouraging results for prediction of tumor response to…”
Get full text

PET and PET-CT in esophageal and gastric cancer by Wieder, Hinrich A, Krause, Bernd J, Herrmann, Ken

“…Esophageal cancer ranks among the ten most common malignancies in the world and is a frequent cause of cancer-related death. Almost all therapeutic modalities…”
Get more information

Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT by Wieder, Hinrich A., MD, Herrmann, Ken, MD

“…PET with the glucose analog [18F]-FDG is increasingly used to monitor tumor response in patients undergoing chemotherapy and chemoradiotherapy. The clinical…”
Get full text

Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagogastric Junction by Wieder, Hinrich A, Beer, Ambros J, Lordick, Florian, Ott, Katja, Fischer, Michael, Rummeny, Ernst J, Ziegler, Sibylle, Siewer, Jorg R, Schwaiger, Markus, Weber, Wolfgang A

“…We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size. Twenty patients with adenocarcinoma of the…”
Get full text

Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival by Wieder, Hinrich A, Rosenberg, Robert, Lordick, Florian, Geinitz, Hans, Beer, Ambros, Becker, Karen, Woertler, Klaus, Dobritz, Martin, Siewert, Jörg R, Rummeny, Ernst J, Stollfuss, Jens C

“…To retrospectively evaluate the prognostic importance of involvement of the circumferential resection margin predicted by using magnetic resonance (MR) imaging…”
Get more information

Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI by Herrmann, Ken, Bundschuh, Ralph A., Rosenberg, Robert, Schmidt, Stefan, Praus, Christine, Souvatzoglou, Michael, Becker, Karen, Schuster, Tibor, Essler, Markus, Wieder, Hinrich A., Friess, Helmut, Ziegler, Sibylle I., Schwaiger, Markus, Krause, Bernd J.

“…Purpose The aim of this study was to compare different analysis methods of 2-deoxy-2-[ 18 F]fluoro- d -glucose positron emission tomography (FDG-PET) and…”
Get full text

PET tracers in musculoskeletal disease beyond FDG by Wieder, Hinrich A, Pomykala, Kelsey L, Benz, Matthias R, Buck, Andreas K, Herrmann, Ken

“…Musculoskeletal tumors comprise a multitude of tumor entities with different grades of malignancy, biological behavior, and therapeutic options. Positron…”
Get more information

Predictive Value of Initial ^sup 18^F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment by Herrmann, Ken, Buck, Andreas K, Schuster, Tibor, Junger, Alexandra, Wieder, Hinrich A, Graf, Nicolas, Ringshausen, Ingo, Rudelius, Martina, Wester, Hans-Jürgen, Schwaiger, Markus, Keller, Ulrich, Dechow, Tobias

“…R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. ^sup…”
Get full text

Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment by Herrmann, Ken, Buck, Andreas K, Schuster, Tibor, Junger, Alexandra, Wieder, Hinrich A, Graf, Nicolas, Ringshausen, Ingo, Rudelius, Martina, Wester, Hans-Jürgen, Schwaiger, Markus, Keller, Ulrich, Dechow, Tobias

“…R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma…”
Get full text

Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18 F-Fluorothymidine by Eckel, Florian, Herrmann, Ken, Schmidt, Stefan, Hillerer, Claudia, Wieder, Hinrich A., Krause, Bernd-Joachim, Schuster, Tibor, Langer, Rupert, Wester, Hans-Jürgen, Schmid, Roland M., Schwaiger, Markus, Buck, Andreas K.

Get full text

Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker ^sup 18^F-Fluorothymidine by Eckel, Florian, Herrmann, Ken, Schmidt, Stefan, Hillerer, Claudia, Wieder, Hinrich A, Krause, Bernd-Joachim, Schuster, Tibor, Langer, Rupert, Wester, Hans-Jürgen, Schmid, Roland M, Schwaiger, Markus, Buck, Andreas K

“…We determined the ability of PET with the thymidine analog 3'-deoxy-3'-^sup 18^F-fluorothymidine (^sup 18^F-FLT) to detect hepatocellular carcinoma (HCC)…”
Get full text

Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18F-Fluorothymidine by Eckel, Florian, Herrmann, Ken, Schmidt, Stefan, Hillerer, Claudia, Wieder, Hinrich A, Krause, Bernd-Joachim, Schuster, Tibor, Langer, Rupert, Wester, Hans-Jurgen, Schmid, Roland M, Schwaiger, Markus, Buck, Andreas K

“…We determined the ability of PET with the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to detect hepatocellular carcinoma (HCC). In this…”
Get full text